activity against both Candida albicans and Aspergillus fumigatus. The MICs of FR901469 against Candida albicans FP633 and Aspergillus fumigatus FP1305 in a micro-broth dilution test were 0.63 and 0.16/zg/ml, respectively. FR901469 showed excellent efficacy by subcutaneous injection against both Candida albicans and Aspergillus fumigatus in a murine systemic infection mode, with ED50s of 0.32 and 0.2 mg/kg, respectively. This compound also showed potent anti-Pneumocystis activity in the nude mice model with experimental Pneumocystis pneumonia. The hemolytic activity of FR901469 towards mouse red blood cells is about 30-fold weaker than that of amphotericin B.
FR901469 that is a non-echinocandin type lipopeptide antibiotic was isolated as a novel antifungal antibiotic from an unidentified fungus No.11243.^This compound is a water-soluble macrocyclic lipopeptidolactone (C71H116N14O23) and has inhibitory activity against 1,3-/3-glucan synthase from Candida albicans. This activity was greater than for the echinocandin-like Iipopeptides2~6) and for the glycolipid papulacandin B7), which are known 1,3-/3-glucan synthase inhibitors. Although the natural echinocandin-like lipopeptides, except for WF1 1 899A with a sulfonate moiety, lack appreciable water-solubility, FR90 1469 showed excellent water-solubility, comparable to WF1 1899A.
The fungal cell wall is an essential structure to fungi and is not present in mammalian cells8'9). As such, it is expected to be a suitable target for antifungal agents and to fulfil the criteria for a safe drug. The cell walls of most fungi contain chitin and /?-glucans, and in Candida albicans, the cell wall macromolecules consist mainly of l,3-j3-glucan. The echinocandin-like lipopeptides10^14^and papulacandins15) indeed displayed excellent anti-Candida activity. Similarly, studies on the cell wall composition of Pneumocystis carinii, knownas the cause of P. carinii pneumoniaand now classified as a fungus, revealed that the l,3-/3-glucan target is an important component of the cell wall in the cyst form, and it is known that inhibitors of glucan synthesis are lethal to P. carinii1'l6'17\
The present report describes the iw vitro and in vivo antifungal activities and hemolytic activity ofFR901469.
Materials and Methods

Compounds
Aculeacin A was a generous gift from Asahi Chemical Hemolytic Activity
Fresh red blood cells prepared from ICR mouse (female, four weeks old) were used in the hemolytic assay. The whole blood cells were collected under heparinized conditions, and washed with saline three times. The resultant red blood cells (RBC) were suspended with saline to yield a 2% (v/v) suspension. Fifty ji\ of RBCsuspension was added to 50ji\ of the compoundsolution which were serially two-fold diluted with saline in U-bottom microtiter plates. The plate was incubated for two hours at room temperature with gentle shaking, and then allowed to stand for a while to settle RBC. The hemolytic activity was determined by visual observation. The minimum lytic concentration (MLC)is defined as the lowest concentration at which the compounds lyse red blood cells.
Statistical Analysis
For statistical analysis, the Student's t test was used. P values of <0.05 were considered significant.
Results
In Vitro Antifungal Activity a)MIC values (ug/ml) were determined using broth (YNBD)microdilution assay. A. fumigatus was also examined and compared with those of WF11899Aand echinocandin B (Table 3 ). The ED5Os of FR901469 in experiment 1 and experiment 2 at day 14 after challenge were 0.5 mg/kg and 0.52 mg/kg, respectively. The efficacy of FR901469 was superior to those of WF11899A and echinocandin B. These two lipopeptide compounds were inactive in this model at doses of 32 mg/kg and 100 mg/kg, respectively. Survival curves for the in vivo aspergillosis model (experiment 2) are shown in Effect of FR90 1469 against Pneumocystis carinii in the Nude Mice Model FR901469 was administered to P. canm'z-infected nude mice to examine its efficacy on the growth of P. carinii cysts in the lungs. As shown in Table 4 , the number ofP. 
Hemolytic Activity
The hemolytic activities of FR901469 and other antifungal agents were tested using mouse red blood cells. As shown in Table 5 , FR901469 was about 30-fold less hemolytic than amphotericin B, but almost the same as echinocandin B.
Discussion
In this study, the in vitro and in vivo antifungal activities of FR901469 were evaluated and compared with those of other antifungal antibiotics.
The results of in vitro study indicated that FR901469 has a favorable spectrum of antifungal activity, especially against the clinically more prevalent fungi such as Candida and Aspergillus spp. This activity was superior to those of echinocandin-like lipopeptides and amphotericin B. Furthermore, an outstanding feature of FR901469 was the good activity in serum against the strains of Candida albicans and Aspergillus fumigatus. Both FR901469 and the echinocandin-like compounds were ineffective against Cryptococcus neoformans. This result suggests that poor penetration or access of the compoundto the target and the metabolic state of the yeast in broth culture may be related to relative resistance1 8).
FR901469 showed good efficacy in systemic infection models in mice infected by clinically relevant C albicans and A. fumigatus, in correlation with its potent activity against these organisms. In particular, the ED50value for 
